
Ever since I was young, I think I wanted to be a scientist.
I also have a passion for helping people.
Being in the Pharmaceutical industry, I'm able to do both, apply kind of my passion in science and use the latest technologies to help bring cures to patients.
I was one of those kids who was interested in science from very early on, probably elementary school or early junior high, I had a high interest in science.
Within two years of each other, my grandmother was diagnosed with uterine cancer and my mother with myelofibrosis.
And so that just pushed me even more to understand what was happening with them and what treatments were available.
And back then there was almost nothing.
That desire to help patients and understand, find treatments or cures or causes of disease drove me into this profession.
So I actually started my career as a dietitian.
Since joining here, it's definitely met my expectations as far as people not just willing to work together, but they'd like to work together.
They want to help you succeed, which I think is terrific. I would say this culture here at this company is so unique.
It #1 is a very welcoming and inclusive environment. And I would say highly collaborative as well.
We're, you know, we're always collaborating. We're always ready to help each other out and we're always ready to uplift each other.
It's, it's just, it's a, it's a really great environment to work in.
The reason why I was drawn to Kyowa Kirin was because of the people I saw the teamwork that that was present in the research team here.
The people who are here have been here for a while, which is very rare for pharmaceutical company.
We've worked with antibodies before, small molecule cell and gene therapy.
And so being able to think about and work on different types of modalities are very, very exciting for scientists.
Using the latest technologies, we're able to almost do anything that we want to try and develop a cure.
One of the big highlights while working on Kyowa Kirin is actually part of my antibody discovery project. We needed an antibody that had a specific property. We weren't sure if it was even possible.
And it turns out not only is it possible, but it works great. I was really happy about that.
I learned something new every day. I've challenged every day and that helps our, our process and our, our work here.
And then it, it goes back to the culture and the people and the collaborate collaboration and being able to walk down the hall and ask someone a question and have a quick chat about the latest research, the latest results from an experiment and what it means for our projects and how to advance that.
Our California
research team
For more than 25 years, our research team in La Jolla, California, has been driving breakthroughs in novel immunotherapies by applying their vast expertise in immune cell biology and antibody engineering. Today, they spearhead our global work on gene and cell therapies aimed at bringing life-changing value to patients.
Strategic areas of focus
Driven to accelerate our research and maximize our impact, we are strategically focused on four pillars of work.
- Three Disease Areas
- Two Innovative Modalities
- Immunology
- Partnerships for Innovation
Disease areas

Hematological cancers and diseases
Our research teams are racing to apply their expertise to discover and develop new treatments for patients living with diseases and cancers affecting blood and blood-forming organs, bone marrow, and related tissues.

Rare diseases
Kyowa Kirin is committed to applying our expertise to rare diseases because we understand that the need is great. There are an estimated 10,000 known rare diseases, of which 95% have no approved treatments.
These diseases impact children and adults, and can be chronic, debilitating, and life-threatening. This also is where the scientific, systemic, and financial challenges can be most acute.
We focus on making a profound impact on the lives of patients and their families and caregivers, and in so doing, strive to become a global leader in Rare Disease therapeutics.

Bone and mineral diseases
Many bone and mineral diseases remain undiagnosed. Lack of treatment in some cases can lead to problems with growth and development. At Kyowa Kirin, we have a long history of treating bone and mineral diseases, particularly those driven by metabolic disorders.
Innovative modalities
For drug discovery and novel therapy realization
Hematopoietic stem cell
gene therapies
We are researching potential treatments for genetic and severe diseases using hematopoietic stem cell gene therapy (HSC-GT) and other cell therapy approaches.
Our approach harnesses the unique power of a patient’s own blood stem cells, also known as hematopoietic stem cells, or HSCs, which have been genetically modified to potentially permanently correct the underlying cause of a genetic disease after a single administration.
We also are developing innovative treatments by combining HSC-GT with the drug discovery technologies and immune-cell and antibody engineering expertise that Kyowa Kirin has cultivated over decades.
In this exciting and fast-evolving area of research, we are exploring allogeneic approaches and other modalities to deliver innovative medicines to more patients around the world.




Advanced therapeutic antibodies
Our aim is to drive the creation of next-generation therapeutic antibodies to address areas of unmet needs.
For decades, Kyowa Kirin has been a leader in developing proprietary therapeutic antibody technologies, and we continue that tradition with our current investment in advanced therapeutic antibody platforms.
For information on licensing any of the following technologies, please contact BioWa team dedicated to working with other industry partners with promising drug candidates.
Potelligent®
This breakthrough antibody technology dramatically enhances the potency and efficacy of antibodies.
Regulgent™ : Our proprietary bi-specific antibody platform
Conventional therapeutic antibodies are limited to binding with just one antigen, while bispecific antibodies can bind to two antigens, making it targeted and increasing efficacy. This dual-binding feature makes it possible to specifically bind to target tissues or cells and work more effectively.
Antibody drug conjugates
Our proprietary monoclonal antibodies specific for tumor-specific antigens have the potential to increases their effectiveness and ability to treat life-threatening diseases.
Immunology

Our expertise in antibody discovery and development has fueled new patents, development programs, and the creation of effective medicines for patients. It also has been at the forefront of key industry advancements, including the ability to safely and reliably reproduce fully human monoclonal antibodies that precisely eliminate target cells that cause disease.
Partnerships for innovation
Our aim is to ensure potential treatments reach those who need them most – and as quickly as possible. Often, this means working in partnership with others. We have worked with this mindset for over a century and have remained steadfastly committed to doing what is best for patients, throughout our many years in life sciences.

Academic partnerships
One of our longest running research collaborations started in 1989 with the La Jolla Institute of Immunology.
This unique partnership has led to many discoveries that have advanced to clinical development and have the potential to meet the medical needs of patients with inflammatory and autoimmune diseases. We have now embarked together on the exciting journey into gene and cell therapy research.

Strategic partnerships
We know that our research may uncover potential breakthroughs in areas beyond our commercial focus. When that happens, we commit to pursue those opportunities in partnership with other industry leaders who can help us reach patients faster. This has led to several partnerships, including a 40-year collaboration with Amgen, bringing eight products to market and changing the standard of care in key disease areas.

Open Innovation
Our Open Innovation Program supports an active exchange of ideas, technology, and resources to drive innovation that can impact lives. We welcome partnerships with industry, startups, biotechs, universities, and researchers.

We put everything into our research. We work hard to produce results. When we succeed, patients can be saved. Our work can also contribute to society. It can create new value. It’s extremely rewarding. We should keep up the challenge to the best of our abilities. We should definitely go on.
There are many steps involved until we produce an effective drug. Many people were involved in the process. We put all our strengths into bringing this drug to the world.
There are many diseases in the world; many people suffering in many ways. Of course, this includes their families. We face such facts head on. And we work hard to provide effective drugs.
The smile of patients – when we see things like that, it encourages us to keep on working. As a pharmaceutical company, we work hard from drug research, from development to production. Our work is involved with life. We take pride in this.
We are truly happy to do our work with pride.
A global pipeline of innovation
Each candidate in our development pipeline reflects our mission to harness innovative science with integrity, responsibility, and urgency to develop transformative medicines that will deliver life-changing value for patients.